ACC 2026: Ventyx’s VTX3232 Phase IIa results show anti-inflammatory benefits in obesity
VTX3232 met its primary endpoints, demonstrating an acceptable safety and tolerability profile.
VTX3232 met its primary endpoints, demonstrating an acceptable safety and tolerability profile.